Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer
Kazia Therapeutics (NASDAQ: KZIA) said it will expand its ongoing Phase 1b trial of paxalisib plus standard-of-care in advanced triple-negative breast cancer, increasing planned enrollment from 12 to 36 patients. The company cited continued safety, tolerability and early clinical activity, aiming to better assess ORR, PFS and biomarkers with pembrolizumab and chemotherapy.
How this was made
The 30-second read
Why it matters
Increasing enrollment should improve statistical/clinical interpretability of ORR, PFS, and translational biomarkers, while the company signals no safety-driven reason for the ASCO abstract withdrawal.
Market read
A concrete clinical development milestone (enrollment tripling) tied to safety/tolerability and expected efficacy/biomarker clarity is a tradable catalyst for KZIA.
What to watch
Abstract withdrawal for IP reasons may reduce near-term external validation/attention (e.g., conference-driven sentiment), even if clinical risk is unchanged.
Background
Kazia’s lead asset paxalisib is an investigational PI3K/Akt/mTOR pathway inhibitor being tested in multiple oncology settings; this update expands a Phase 1b TNBC combination study.
Ticker impact
Kazia plans to expand its Phase 1b paxalisib + pembrolizumab/chemotherapy trial in advanced TNBC enrollment from 12 to 36 patients.
Near-term upside bias as trial expansion de-risks development progress; magnitude likely capped by early-stage, small open-label data.
The company explicitly ties the enrollment increase to continued encouraging safety/tolerability and expects more meaningful ORR/PFS and biomarker assessment from a larger dataset.
Market effects
Reinforces investor focus on PI3K/mTOR pathway inhibitors combined with immunotherapy in TNBC, potentially improving sentiment for similar mechanism programs.
Primarily impacts US-listed biotech sentiment; limited direct regional spillover beyond clinical-stage oncology peers.
TNBC remains a global unmet-need area; positive trial momentum can influence broader oncology development expectations.
Counterpoint
Enrollment expansion does not guarantee improved efficacy; early Phase 1b ORR/PFS may remain underwhelming despite better biomarker resolution.
Key entities
- companyKazia Therapeutics
Sponsor of the paxalisib Phase 1b trial in advanced triple-negative breast cancer.
- drugpaxalisib
Investigational brain-penetrant PI3K/Akt/mTOR pathway inhibitor being evaluated in combination regimens.
- drugpembrolizumab
Checkpoint inhibitor used in combination with paxalisib and chemotherapy in the expanded trial.
